No abstract

BACKGROUND: Early preeclampsia is associated with significant placental hypoperfusion. We explore the diagnostic value of placental diffusion-derived vessel density, a biomarker derived from diffusion-weighted magnetic resonance imaging, which measures in vivo vessel microperfusion, in the differential diagnosis of normal and early preeclampsia pregnancies. METHODS: This was a prospective study involving 29 controls and 17 singleton pregnancies affected by early preeclampsia. Nineteen pregnancies from 28 to 34 weeks of gestational age were included from the normal group for a comparison with the early preeclampsia group. Using a 3.0 T magnetic resonance imaging scanner, diffusion-weighted images were obtained with the diffusion weighting b values of 0, 20, and 40 s/mm 2 . DDVD mean was the mean of DDVD b0b20 and DDVD b0b40 , while DDVD b0b20 and DDVD b0b40 refer to the diffusion-derived vessel density values computed from b =0 and 20 s/mm 2 images, and from b =0 and 40 s/mm 2 images, respectively. The correlation between DDVD mean and gestational age was examined using a linear regression model. The area under the curve of the DDVD mean for early preeclampsia pregnancies detection was calculated by the receiver operating characteristic analysis. RESULTS: As gestational age increased, DDVD mean linearly decreased. DDVD mean was significantly decreased in the early preeclampsia pregnancies compared with the normal pregnancies (52.72±46.73 versus 213.34±93.50 au/pixel; P <0.001). The area under the curve (DDVD mean ) for discriminating between normal and early preeclampsia pregnancies regardless of fetal growth restriction was 0.954, and the area under the curve was 1.000 when early preeclampsia pregnancies without fetal growth restriction were excluded. CONCLUSIONS: DDVD mean , an in vivo vessel microperfusion measure, allowed total separation of normal and early preeclampsia pregnancies.

Objective To compare survival outcomes of different postoperative adjuvant therapies (PATs) for early‐stage cervical cancer (ECC) patients with one intermediate‐risk pathological factor (IPF). Methods A total of 2889 patients with stage IA1 to IIA2 cervical cancer were included in this study. Three PAT groups were identified, namely a no adjuvant therapy (NAT) group (n = 773), an adjuvant radiotherapy/chemoradiotherapy (ART) group (n = 1648) and an adjuvant chemotherapy (ACT) group (n = 468). Kaplan–Meier analysis and COX regression analysis were used to compare the overall survival (OS) and disease‐free survival (DFS) among the three groups, before and after propensity score matching (PSM). Results The recurrence and mortality rate rates in the NAT, ART and ACT groups were 9.2%, 8.6%, and 7.9%, respectively (p = 0.737). Kaplan–Meier analysis demonstrated no significant differences in the NAT, ART, and ACT groups in 5‐year OS rates (92.8% vs. 93.6% vs. 94.7%, p = 0.594) and DFS rates (88.7% vs. 89.6% vs. 90.5%, p = 0.772). Post‐hoc tests yielded similar results, with no differences in 5‐year OS and DFS (NAT vs. ART, before and after matching, p > 0.05); (NAT vs. ACT, before and after matching, p > 0.05); and (ACT vs. ART, before and after matching, p > 0.05). Conclusion Postoperative adjuvant radiotherapy, chemoradiotherapy, and chemotherapy are not associated with survival outcomes of ECC patients with one IPF. Considering the side effects and impact on patients' quality of life, the PATs should be carefully considered.